COX-2 inhibitors with a methylsulfoxide pharmacophore

Abstract

Novel methylsulfoxide analogues, of known selective cyclooxygenase-2 (COX-2) inhibitors, with a methylsulfone moiety are claimed as COX-2 inhibitors. The inhibitors are useful for the treatment of COX-2-mediated disorders comprising inflammation and inflammation-associated disorders. The clinical applicability for development of the claimed sulfoxide analogues as COX-2 inhibitors is eval-uated against the car-diovascular and gastrointestinal safety.

Keywords::

• cardiovascular safety
• cyclooxygenase-2 (COX-2)
• gastrointestinal safety
• prodrug